| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,990,000 |
| Market
Cap: |
631.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$12.17 - $24.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
57,878 |
180,115 |
180,115 |
210,533 |
| Total Sell Value |
$1,203,255 |
$3,323,210 |
$3,323,210 |
$4,306,417 |
| Total People Sold |
2 |
2 |
2 |
3 |
| Total Sell Transactions |
4 |
8 |
8 |
15 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-10-18 |
4 |
AS |
$61.22 |
$308,890 |
D/D |
(5,000) |
17,669 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-10-18 |
4 |
OE |
$12.10 |
$60,500 |
D/D |
5,000 |
22,669 |
|
- |
|
| Simpson Curran |
SVP, Technical Operations |
• – – |
2018-10-16 |
4 |
AS |
$60.85 |
$3,791,503 |
D/D |
(62,309) |
39,500 |
|
- |
|
| Simpson Curran |
SVP, Technical Operations |
• – – |
2018-10-16 |
4 |
OE |
$13.09 |
$1,314,223 |
D/D |
62,309 |
42,167 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-10-16 |
4 |
AS |
$61.18 |
$637,129 |
D/D |
(10,414) |
0 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-10-16 |
4 |
OE |
$0.85 |
$8,852 |
D/D |
10,414 |
10,414 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-10-15 |
4 |
AS |
$58.93 |
$445,275 |
D/D |
(7,500) |
137,283 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-10-15 |
4 |
AS |
$58.73 |
$445,745 |
D/D |
(7,510) |
326,000 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-10-15 |
4 |
AS |
$58.83 |
$593,412 |
D/D |
(10,000) |
0 |
|
- |
|
| Yoo Stephen |
Chief Medical Officer |
• – – |
2018-10-15 |
4 |
OE |
$0.85 |
$8,500 |
D/D |
10,000 |
10,000 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2018-10-08 |
4 |
AS |
$62.79 |
$1,275,914 |
D/D |
(20,000) |
0 |
|
- |
|
| Danos Olivier |
Chief Scientific Officer |
• – – |
2018-10-08 |
4 |
OE |
$20.35 |
$407,000 |
D/D |
20,000 |
20,000 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-09-17 |
4 |
OE |
$0.85 |
$25,500 |
D/D |
30,000 |
144,783 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-09-17 |
4 |
AS |
$70.43 |
$561,472 |
D/D |
(7,500) |
114,783 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-09-17 |
4 |
AS |
$70.46 |
$562,564 |
D/D |
(7,510) |
333,510 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-08-27 |
4 |
AS |
$66.29 |
$499,118 |
D/D |
(7,510) |
341,020 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-08-27 |
4 |
OE |
$0.85 |
$123,250 |
D/D |
145,000 |
348,530 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-08-20 |
4 |
AS |
$65.75 |
$329,806 |
D/D |
(5,000) |
17,669 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-08-20 |
4 |
OE |
$12.10 |
$60,500 |
D/D |
5,000 |
22,669 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-08-15 |
4 |
AS |
$65.31 |
$490,710 |
D/D |
(7,500) |
122,283 |
|
- |
|
| Vasista Vittal |
Chief Financial Officer |
• – – |
2018-07-16 |
4 |
AS |
$74.19 |
$566,522 |
D/D |
(7,500) |
129,783 |
|
- |
|
| Mills Kenneth T. |
President and CEO |
• • – |
2018-06-20 |
4 |
AS |
$61.70 |
$331,018 |
D/D |
(5,000) |
203,530 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-06-19 |
4 |
OE |
$12.10 |
$18,489 |
D/D |
1,528 |
17,669 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-06-18 |
4 |
AS |
$55.25 |
$283,886 |
D/D |
(5,000) |
16,141 |
|
- |
|
| Christmas Patrick J. |
SVP, General Counsel |
• – – |
2018-06-18 |
4 |
OE |
$12.10 |
$60,500 |
D/D |
5,000 |
21,141 |
|
- |
|
406 Records found
|
|
Page 11 of 17 |
|
|
